Investing.com -- US stock futures were muted on Tuesday, as investors eyed an upcoming inflation report and potential Federal Reserve interest rate cuts.
By 08:06 ET (12:06 GMT), the Dow futures contract was mostly unchanged, S&P 500 futures had edged up by 5 points or 0.1%, and Nasdaq 100 futures had ticked up by 12 points or 0.1%.
Here are some of the biggest premarket US stock movers today.
- Shares in Apple (NASDAQ:AAPL) inched lower in premarket US trading on Tuesday after the tech giant revealed the latest artificial intelligence-enhanced iterations of its flagship iPhone and the European Union's top court ruled against the company in a years-long legal battle regarding its taxes in Ireland.
- Oracle (NYSE:ORCL) shares rose sharply before the opening bell after the group reported better-than-expected fiscal first-quarter results, driven by strong demand for its cloud business. The Texas-based cloud services company also said it signed a strategic partnership with Amazon (NASDAQ:AMZN) Web Services that will allow customers to access Oracle Autonomous Database and Oracle Exadata Database Service within AWS.
- Alibaba 's American Depositary Receipts (ADRs) (NYSE:BABA) have risen more than 2% premarket as investors reacted to the news of its inclusion on China's mainland stock exchanges. Alibaba announced its inclusion in the Southbound (SB) Connect late on Monday. It comes after the Chinese e-commerce company upgraded its listing in Hong Kong to primary status last month, paving the way for it to be added to China's Shanghai and Shenzhen stock exchanges Stock Connect Scheme.
- Shares of Rubrik (NYSE:RBRK) fell following the data security group's second-quarter results, which raised concerns among investors about its performance of the rest of its fiscal year.
- Mission Produce (NASDAQ:AVO) shares soared after the avocado supplier posted better-than-anticipated third-quarter revenue.
- Viridian Therapeutics (NASDAQ:VRDN) announced that its experimental treatment for patients suffering from thyroid eye disease significantly brought down eye inflammation in a late-stage trial.